多发性骨髓瘤（MM）是一种在骨髓中生成 M 蛋白的浆细胞异常增殖的一种恶性克隆病，在 所有的恶性血液疾病中，它的发生率是第 2 位的。近 20 年间，随着蛋白酶体抑制剂、免疫调节药物、皮质 类固醇等化学制剂的广泛使用，提高了 MM 的生存率。皮质类固醇是 MM 联合化疗的一线药物，但几乎所 有的 MM 会在后期治疗中复发或者产生耐药性，因此探究 MM 对皮质类固醇的耐药机制，增强 MM 对地塞 米松的敏感性，有利于加深对MM 的认知，为改善患者疾病预后提供新的治疗方案。

Multiple myeloma（MM）is a malignant clonal cancer of plasma cell characterized by overpro⁃ duction of abnormal plasma cells in the bone marrow and skeletal destruction. Its incidence rate ranks the second among all malignant hematologic diseases. With a widespread usage of protease inhibitors，immunomodulators， corticosteroids and other chemicals，the survival rate of MM has substantially improved in the past 20 years. Corti⁃ costeroids are the first⁃line drug of MM combination chemotherapy，but almost all MM will relapse or become drug resistance in later treatment. There fore，exploring the mechanism of MM′s drug resistance to corticosteroids and enhancing MM′s sensitivity to dexamethasone will provide a a improved treatment plan to the patients prognosis and deeper understanding of MM.